
Helen Parfrey

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4557359/publications.pdf Version: 2024-02-01



HELEN DADEDEV

#	Article	IF	CITATIONS
1	Genetic variants associated with susceptibility to idiopathic pulmonary fibrosis in people of European ancestry: a genome-wide association study. Lancet Respiratory Medicine,the, 2017, 5, 869-880.	5.2	233
2	Genome-Wide Association Study of Susceptibility to Idiopathic Pulmonary Fibrosis. American Journal of Respiratory and Critical Care Medicine, 2020, 201, 564-574.	2.5	208
3	An epithelial biomarker signature for idiopathic pulmonary fibrosis: an analysis from the multicentre PROFILE cohort study. Lancet Respiratory Medicine,the, 2017, 5, 946-955.	5.2	190
4	Outcome of Hospitalization for COVID-19 in Patients with Interstitial Lung Disease. An International Multicenter Study. American Journal of Respiratory and Critical Care Medicine, 2020, 202, 1656-1665.	2.5	171
5	Treating idiopathic pulmonary fibrosis with the addition of co-trimoxazole: a randomised controlled trial. Thorax, 2013, 68, 155-162.	2.7	161
6	Targeting a Surface Cavity of α1-Antitrypsin to Prevent Conformational Disease. Journal of Biological Chemistry, 2003, 278, 33060-33066.	1.6	59
7	α1-Antitrypsin deficiency, liver disease and emphysema. International Journal of Biochemistry and Cell Biology, 2003, 35, 1009-1014.	1.2	58
8	Inhibiting Polymerization. American Journal of Respiratory Cell and Molecular Biology, 2004, 31, 133-139.	1.4	57
9	Development of a Consensus Statement for the Definition, Diagnosis, and Treatment of Acute Exacerbations of Idiopathic Pulmonary Fibrosis Using the Delphi Technique. Advances in Therapy, 2015, 32, 929-943.	1.3	52
10	Effect of Co-trimoxazole (Trimethoprim-Sulfamethoxazole) vs Placebo on Death, Lung Transplant, or Hospital Admission in Patients With Moderate and Severe Idiopathic Pulmonary Fibrosis. JAMA - Journal of the American Medical Association, 2020, 324, 2282.	3.8	32
11	Use of mycophenolate mofetil and azathioprine for the treatment of chronic hypersensitivity pneumonitis—A singleâ€centre experience. Clinical Respiratory Journal, 2019, 13, 791-794.	0.6	31
12	Reduced Ets Domain-containing Protein Elk1 Promotes Pulmonary Fibrosis via Increased Integrin αvβ6 Expression. Journal of Biological Chemistry, 2016, 291, 9540-9553.	1.6	30
13	Safety and tolerability of nintedanib for the treatment of idiopathic pulmonary fibrosis in routine UK clinical practice. ERJ Open Research, 2018, 4, 00049-2018.	1.1	24
14	Inhibition of mast cells: a novel mechanism by which nintedanib may elicit anti-fibrotic effects. Thorax, 2020, 75, 754-763.	2.7	24
15	The Efficacy and Mechanism Evaluation of Treating Idiopathic Pulmonary fibrosis with the Addition of Co-trimoxazole (EME-TIPAC): study protocol for a randomised controlled trial. Trials, 2018, 19, 89.	0.7	19
16	Treating Idiopathic Pulmonary Fibrosis with the Addition of Co-Trimoxazole: An Economic Evaluation Alongside a Randomised Controlled Trial. Pharmacoeconomics, 2014, 32, 87-99.	1.7	18
17	Idiopathic pulmonary fibrosis in the UK: analysis of the British Thoracic Society electronic registry between 2013 and 2019. ERJ Open Research, 2021, 7, 00187-2020.	1.1	17
18	Sensitization of the UPR by loss of PPP1R15A promotes fibrosis and senescence in IPF. Scientific Reports, 2021, 11, 21584.	1.6	13

HELEN PARFREY

#	Article	IF	CITATIONS
19	Patient Reported Experiences and Delays During the Diagnostic Pathway for Pulmonary Fibrosis: A Multinational European Survey. Frontiers in Medicine, 2021, 8, 711194.	1.2	8
20	Author's response: co-trimoxazole treatment in idiopathic pulmonary fibrosis. Thorax, 2013, 68, 884-885.	2.7	7
21	Identifying causation in hypersensitivity pneumonitis: a British perspective. BMJ Open Respiratory Research, 2019, 6, e000469.	1.2	6
22	P147 Safety of AbatacePt in Rheumatoid arthritis associated Interstitial Lung disease (APRIL). Rheumatology, 2021, 60, .	0.9	1
23	Co-trimoxazole to reduce mortality, transplant, or unplanned hospitalisation in people with moderate to very severe idiopathic pulmonary fibrosis: the EME-TIPAC RCT. Efficacy and Mechanism Evaluation, 2021, 8, 1-110.	0.9	1
24	First insights from the BTS idiopathic pulmonary fibrosis (IPF) registry. , 2016, , .		1
25	Targeting a Surface Cavity of α1-Antitrypsin to Prevent Conformational Disease. Clinical Science, 2003, 104, 57P-57P.	0.0	0
26	The hidden costs of living with systemic sclerosisâ€associated interstitial lung disease. Respirology, 2022, , .	1.3	0